Chronic constipation and irritable bowel syndrome (IBS) are functional gastrointestinal disorders that significantly affect patients' quality of life. Chronic constipation and IBS are prevalent-12% of the US population meet the diagnostic criteria for IBS, and 15% meet the criteria for chronic constipation- and these conditions negatively impact the healthcare system from an economic perspective. Despite attempts at dietary modification, exercise, or use of over-the-counter medications, many patients have persistent symptoms. Alternative treatment options are limited. This article describes linaclotide (Linzess, Ironwood Pharmaceuticals/Forest Pharmaceuticals), a new, firstin- class medication for the treatment of chronic constipation and constipation-predominant IBS.
|Original language||English (US)|
|Number of pages||8|
|Journal||Gastroenterology and Hepatology|
|State||Published - Oct 2012|
All Science Journal Classification (ASJC) codes